TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
RGC

Regencell Bioscience Holdings Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

6.20$ +0.0% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns Regencell Bioscience Holdings Ltd (RGC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 11.4% of the shares are freely tradable; institutional investors hold 0.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 0.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 88.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 11.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 1.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 495Mio.

Largest Shareholders

Institutions

Institutions RGC
Name Stake (%) Shares Change (%) Date
Geode Capital Management, LLC 0.08 415,569 +0.6 03/31/2026
Quadrature Capital Limited 0.01 41,750 +0.0 06/30/2026
Marex Group Ltd 0.01 31,600 +0.0 03/31/2026
Vident Advisory, LLC 0.01 29,588 -1.2 03/31/2026
Squarepoint Ops LLC 0.01 26,613 +2.3 03/31/2026
UBS Group AG 0.00 23,885 +31.2 03/31/2026
Fox Run Management LLC 0.00 20,691 +0.0 06/30/2026
Morgan Stanley - Brokerage Accounts 0.00 20,078 -6.3 03/31/2026

Funds

Funds RGC
Name Stake (%) Shares Change (%) Date
Fidelity Nasdaq Composite Index 0.06 301,859 +0.5 07/31/2026
Fidelity Nasdaq Composite ETF 0.02 121,570 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?